HC Wainwright Raises Earnings Estimates for Cabaletta Bio

Cabaletta Bio, Inc. (NASDAQ:CABA) – HC Wainwright upped their Q3 2026 earnings per share estimates for shares of Cabaletta Bio in a research note issued to investors on Friday, August 14th. HC Wainwright analyst D. Tsao now expects that the company will earn ($0.31) per share for the quarter, up from their prior estimate of ($0.36). The consensus estimate for Cabaletta Bio’s current full-year earnings is ($1.34) per share. HC Wainwright also issued estimates for Cabaletta Bio’s Q4 2026 earnings at ($0.31) EPS, FY2026 earnings at ($1.35) EPS, Q1 2027 earnings at ($0.31) EPS, Q2 2027 earnings at ($0.31) EPS, Q3 2027 earnings at ($0.33) EPS, Q4 2027 earnings at ($0.33) EPS, FY2027 earnings at ($1.29) EPS, FY2028 earnings at ($0.74) EPS, FY2029 earnings at ($0.68) EPS and FY2030 earnings at $0.89 EPS.

Other equities research analysts have also recently issued research reports about the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Cabaletta Bio in a research note on Friday, July 17th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Cabaletta Bio in a report on Wednesday, June 3rd. Wall Street Zen lowered shares of Cabaletta Bio from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th. Wells Fargo & Company cut their target price on shares of Cabaletta Bio from $4.00 to $3.00 and set an “equal weight” rating for the company in a research note on Friday. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $30.00 price target on shares of Cabaletta Bio in a research report on Monday, May 4th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Cabaletta Bio presently has an average rating of “Moderate Buy” and an average price target of $15.33.

Cabaletta Bio Price Performance

Cabaletta Bio stock opened at $2.89 on Tuesday. The stock has a market capitalization of $471.23 million, a PE ratio of -1.84 and a beta of 3.30. The business has a 50 day simple moving average of $2.88 and a 200-day simple moving average of $3.06. Cabaletta Bio has a 12 month low of $1.40 and a 12 month high of $4.23.

Cabaletta Bio (NASDAQ:CABA) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.03.

Institutional Trading of Cabaletta Bio

Large investors have recently made changes to their positions in the company. Legal & General Group Plc acquired a new position in Cabaletta Bio in the 2nd quarter valued at $34,000. Kestra Advisory Services LLC purchased a new position in Cabaletta Bio in the 1st quarter valued at $32,000. SummitTX Capital L.P. acquired a new stake in Cabaletta Bio during the 1st quarter worth $34,000. China Universal Asset Management Co. Ltd. acquired a new stake in Cabaletta Bio during the 4th quarter worth $34,000. Finally, ANTIPODES PARTNERS Ltd purchased a new stake in shares of Cabaletta Bio during the fourth quarter worth $38,000.

Trending Headlines about Cabaletta Bio

Here are the key news stories impacting Cabaletta Bio this week:

• Positive Sentiment: HC Wainwright raised its EPS forecasts for Cabaletta Bio’s third and fourth quarters of 2026 to approximately $(0.31) from $(0.36), and increased its full-year 2026 loss estimate to $(1.35) from $(1.51). The firm also reduced projected losses for 2027 and 2028, including raising FY2027 EPS to $(1.29) from $(1.48) and FY2028 EPS to $(0.74) from $(1.41). These revisions suggest improving expectations for the company’s cost structure or cash runway.
• Neutral Sentiment: Despite the upgrades, HC Wainwright still expects Cabaletta Bio to remain unprofitable through 2029, with a forecasted return to positive EPS of $0.89 in 2030. The current-year consensus remains a loss of approximately $(1.34) per share, highlighting the stock’s dependence on clinical and commercial progress rather than near-term earnings.
• Negative Sentiment: HC Wainwright lowered its FY2029 EPS forecast to $(0.68) from $(0.64) and its FY2030 forecast to $0.89 from $1.11. These cuts temper the benefit of the earlier-year estimate increases and imply a slower long-term earnings trajectory.
• Negative Sentiment: Wells Fargo cut its Cabaletta Bio price target to $3.00. With the shares recently near $2.89, the revised target indicates limited near-term upside and may weigh on investor sentiment. Wells Fargo Cuts Cabaletta Bio Price Target

Cabaletta Bio Company Profile

Cabaletta Bio is a clinical-stage biotechnology company pioneering chimeric autoantibody receptor T cell (CAAR-T) therapies for B cell–mediated autoimmune diseases. Its proprietary platform engineers patient-derived T cells to selectively target and eliminate pathogenic B cells that produce disease-driving autoantibodies, with the aim of preserving overall immune function and reducing off-target toxicity.

The company’s lead candidate, DSG3-CAART, is being evaluated in pemphigus vulgaris, a rare blistering disorder caused by autoantibodies against desmoglein 3.